rotigotine
Brand: Neupro
Beers Criteria Prototype: levodopa-carbidopa
Drug Class: dopamine agonist
Drug Family: antiparkinsonian
Subclass: non-ergot transdermal dopamine agonist
Organ Systems: cns
Mechanism of Action
Broadest receptor profile among non-ergot dopamine agonists; activates D1-D3 receptors with alpha-2 and 5-HT1A activity. Transdermal delivery provides continuous dopaminergic stimulation, avoiding the pulsatile peaks of oral formulations, which is theoretically advantageous for minimizing motor fluctuations.
D1 dopamine receptorD2 dopamine receptorD3 dopamine receptoralpha-2 adrenergic receptor5-HT1A receptor
Indications
- Parkinson's disease (early and advanced)
- moderate to severe restless legs syndrome
Contraindications
- MRI incompatibility (patch contains metal foil; must remove before MRI)
Adverse Effects
Common
- application site reactions (most common)
- nausea
- somnolence
- dizziness
Serious
- sudden onset sleep
- impulse control disorders
- symptomatic hypotension
- hallucinations
Pharmacokinetics (ADME)
| Absorption | transdermal; continuous absorption over 24 hours; bioavailability ~37% |
| Distribution | protein binding ~92%; Vd ~84 L/kg |
| Metabolism | extensive first-pass if oral; transdermal delivery avoids this; primarily conjugation |
| Excretion | renal (~71%) and fecal (~23%) |
| Half-life | 5-7 hours (but continuous transdermal delivery maintains steady-state) |
| Onset | steady-state achieved within 2-3 days of patch use |
| Peak | continuous (no peak with patch) |
| Duration | 24 hours per patch |
| Protein Binding | 92% |
| Vd | 84 L/kg |
Drug Interactions
| Drug / Agent | Mechanism | Severity |
|---|---|---|
| dopamine antagonists | pharmacodynamic antagonism | major |
| CNS depressants | additive somnolence | moderate |
Nursing Considerations
- Instruct patient to remove the patch before MRI; the patch contains metal backing that can cause burns during MRI.
- Apply to clean, dry, hairless skin; rotate sites daily; avoid applying to oily skin or areas with inflammation — poor adhesion or skin reactions are the most common reasons for discontinuation.
- Patients with RLS should apply the patch in the evening; for Parkinson's, morning application is recommended to maintain daytime dopaminergic coverage.
- Monitor for same impulse control disorders, sleep attacks, and orthostatic hypotension as with other dopamine agonists.
Clinical Pearls
- Rotigotine's transdermal delivery provides 24-hour continuous dopaminergic stimulation, which is theoretically closer to physiological tonic dopamine release than pulsatile oral dosing — this may reduce wearing-off phenomena in Parkinson's disease.
- For patients with dysphagia who cannot take oral Parkinson's medications, the rotigotine patch offers a non-oral route that bypasses swallowing difficulty.
Safety Profile
Pregnancy avoid
Lactation avoid
Renal Adjustment Not required
Hepatic Adjustment Required
TDM Not required
Concordance Terms
Cross-referenced clinical concepts — click any term to see all content where it appears.